These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16859431)

  • 1. Samarium for osteoblastic bone metastases and osteosarcoma.
    Anderson P
    Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
    Anderson P; Nuñez R
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
    Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
    J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
    Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
    J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
    Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
    Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
    Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
    Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Samarium 153Sm lexidronam.
    Lamb HM; Faulds D
    Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
    Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
    J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
    Anderson PM; Wiseman GA; Erlandson L; Rodriguez V; Trotz B; Dubansky SA; Albritton K
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6895-900. PubMed ID: 16203780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone.
    Alberts AS; Smit BJ; Louw WK; van Rensburg AJ; van Beek A; Kritzinger V; Nel JS
    Radiother Oncol; 1997 May; 43(2):175-9. PubMed ID: 9192964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Samarium-153-EDTMP biodistribution and dosimetry estimation.
    Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
    J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
    van Rensburg AJ; Alberts AS; Louw WK
    J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.
    Loeb DM; Hobbs RF; Okoli A; Chen AR; Cho S; Srinivasan S; Sgouros G; Shokek O; Wharam MD; Scott T; Schwartz CL
    Cancer; 2010 Dec; 116(23):5470-8. PubMed ID: 20715156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
    Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
    Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS; Quick DP; Bushnell D; Sartor O
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
    Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
    J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biospeciation, by potentiometry and computer simulation, of Sm-EDTMP, a bone tumor palliative agent.
    Charmaine de Witt G; May PM; Webb J; Hefter G
    Biometals; 1996 Oct; 9(4):351-61. PubMed ID: 8837456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.